Pharmacogenomic Targets in Mood Disorders: Circa 2016

Mark A. Frye, M.D.

Introduction

Dr. Frye received his medical degree from the University of Minnesota School of Medicine and completed his psychiatric training at the UCLA Neuropsychiatric Institute. He subsequently completed a research fellowship in the Biological Psychiatry Branch at the National Institute of Mental Health in Bethesda, Maryland. While at NIMH, his research focused on the neurobiology of depression and bipolar disorder.  Dr. Frye’s current research centers on genomics, brain imaging and neuroendocrinology of mood disorders and alcoholism, complementing his clinical interests in bipolar disorder, depression and alcoholism. Dr. Frye and his team established the Mayo Clinic Individualized Medicine Biobank for Bipolar Disorder in an effort to identify and understand the underpinning mechanisms of bipolar disorders through genomic studies. He receives research support from the National Institute of Mental Health, Mayo Clinic's Samuel C. Johnson Genomics of Addiction Program, SC Johnson Giving, Inc., and Mayo Clinic Center for Individualized Medicine. He has also received funding from the National Institute on Alcohol Abuse and Alcoholism. He is frequently invited to give presentations on his research both domestically and internationally.  Dr. Frye serves on the editorial boards of International Journal of Bipolar Disorders and World Journal of Psychiatry and as scientific reviewer for the Interventions Committee for Adult Disorders, National Institute of Mental Health. He also serves on the Scientific Advisory Committee to the Depression and Bipolar Support Alliance. He is an active author, publishing numerous papers in peer-reviewed publications as well as book chapters and abstracts. In addition to his clinical and research activities, Dr. Frye is active in education. He holds full master’s faculty privileges in Clinical and Translational Sciences at Mayo Graduate School and has provided mentorship to many residents, research fellows and assistant professors.  Dr. Frye has received multiple honors and awards both as an educator and researcher, including the Mogens Schou Award for Education from the International Society for Bipolar Disorder, two Mayo Clinic Rome Mentorship Awards and the Gerald Klerman Senior Investigator Award from the Depression and Bipolar Support Alliance.

Learning Objectives

• review pharmacokinetic genetic variation of psychotropic drugs.  
• review the impact of genetic variation on the pharmacogenomics of drug response or adverse event.
• ​translate how these research advances may impact practice.

Live webcast available at:  http://videos.mayo.edu/live
1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live.  MedHub will be implemented for all post presentation surveys.  Your name and e-mail are not linked to your evaluation. Identifiers are tracked separately for attendance records only.  To document your attendance, please send an email to rstpsychgr@mayo.edu. The badge reader should continue to be utilized for Gonda and Sister Helen Hayes locations.

Credit Statements

• Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
• Mayo Clinic College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

Disclosure Summary
As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development), must ensure balance, independence, objectivity and scientific rigor in its educational activities.   Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry: 

Mark Frye, MD -

Grant Support:  AssureRx, Janssen Research & Development, Mayo Foundation, Myriad, National Institute of Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), Pfizer

Consultant (Mayo):   Janssen Research & Development, LLC, Mitsubishi Tanabe Pharma Corporation, Myriad Genetics, Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals, Neuralstem, Inc.

CME/Travel Support:  American Physician Institute, CME Outfitters

 
No relevant financial relationship(s) with industry:
Brian Palmer, M.D., Michael Bostwick, M.D., Karen Grothe, Ph.D., Lois Krahn, M.D., Jarrod Leffler, Ph.D., Larissa Loukianova, M.D., Mary Machulda, Ph.D., Patricia Maus, M.D., Amber Pearson, Jeffrey Staab, M.D., Cosima Swintak, M.D., Kristin Vickers Douglas, Ph.D., Cynthia Harbeck-Weber, Ph.D., Michael Zaccariello, Ph.D., Georgina Rink

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

Product(s)/Device(s): Antidepressants in Bipolar Disorder

Questions regarding this program can be directed to Charlene Nelson at nelson.charlene1@mayo.edu